PARAMEDIC 2: The Adrenaline Trial

Conditions

Out of hospital cardiac arrest Circulatory System Cardiac arrest

Ji C, Pocock H, Deakin CD, Quinn T, Nolan JP, Rees N, Charlton K, Finn J, Rosser A, Lall R, Perkins GD.

2025-02-042 citations

10.1016/j.resplu.2025.100890

Adrenaline to improve survival in out-of-hospital cardiac arrest: the PARAMEDIC2 RCT

Gavin D. Perkins, Chen Ji, Felix Achana, John J. Black, Karl Charlton et al. (32 authors)

Health Technology Assessment2021-04-0116 citations

10.3310/hta25250

Cost-effectiveness of adrenaline for out-of-hospital cardiac arrest.

Achana F, Petrou S, Madan J, Khan K, Ji C, Hossain A, Lall R, Slowther AM, Deakin CD, Quinn T, Nolan JP, Pocock H, Rees N, Smyth M, Gates S, Gardiner D, Perkins GD, PARAMEDIC2 Collaborators.

2020-09-2727 citations

10.1186/s13054-020-03271-0

Intraosseous versus intravenous administration of adrenaline in patients with out-of-hospital cardiac arrest: a secondary analysis of the PARAMEDIC2 placebo-controlled trial.

Nolan JP, Deakin CD, Ji C, Gates S, Rosser A, Lall R, Perkins GD.

2020-01-3042 citations

10.1007/s00134-019-05920-7

Bayesian group sequential designs for phase III emergency medicine trials: a case study using the PARAMEDIC2 trial.

Ryan EG, Stallard N, Lall R, Ji C, Perkins GD, Gates S.

2020-01-1410 citations

10.1186/s13063-019-4024-x

The influence of time to adrenaline administration in the Paramedic 2 randomised controlled trial.

Perkins GD, Kenna C, Ji C, Deakin CD, Nolan JP, Quinn T, Scomparin C, Fothergill R, Gunson I, Pocock H, Rees N, O'Shea L, Finn J, Gates S, Lall R.

2020-01-0757 citations

10.1007/s00134-019-05836-2

The effects of adrenaline in out of hospital cardiac arrest with shockable and non-shockable rhythms: Findings from the PACA and PARAMEDIC-2 randomised controlled trials.

Perkins GD, Kenna C, Ji C, Deakin CD, Nolan JP, Quinn T, Fothergill R, Gunson I, Pocock H, Rees N, Charlton K, Finn J, Gates S, Lall R.

2019-05-1949 citations

10.1016/j.resuscitation.2019.05.007

A Randomized Trial of Epinephrine in Out-of-Hospital Cardiac Arrest

Gavin D. Perkins, Chen Ji, Charles D. Deakin, Tom Quinn, Jerry P. Nolan et al. (24 authors)

New England Journal of Medicine2018-07-18751 citations

10.1056/nejmoa1806842

Pre-hospital Assessment of the Role of Adrenaline: Measuring the Effectiveness of Drug administration In Cardiac arrest (PARAMEDIC-2): Trial protocol.

Perkins GD, Quinn T, Deakin CD, Nolan JP, Lall R, Slowther AM, Cooke M, Lamb SE, Petrou S, Achana F, Finn J, Jacobs IG, Carson A, Smyth M, Han K, Byers S, Rees N, Whitfield R, Moore F, Fothergill R, Stallard N, Long J, Hennings S, Horton J, Kaye C, Gates S.

2016-09-1740 citations

10.1016/j.resuscitation.2016.08.029

Interventions

Intervention: Adrenaline 1 mg every 5 minutes Control: Placebo

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Cardiac arrest in out of hospital environment 2. Advanced life support initiated and/or continued by ambulance service clinician

Exclusion criteria

Exclusion criteria: 1. Known or apparent pregnancy 2. Known or apparently aged under 16 years 3. Cardiac arrest secondary to anaphylaxis 4. Adrenaline given prior to arrival of ambulance service clinician

Design outcomes

Primary

Measure	Time frame
Survival to 30 days post cardiac arrest	—

Secondary

Measure	Time frame
1. Survived event (sustained ROSC, with spontaneous circulation until admission and transfer of care to medical staff at the receiving hospital) 2. Survival to hospital discharge (the point at which the patient is discharged from the hospital acute care unit regardless of neurological status, outcome or destination) 3, 6 and 12 months 3. Neurological outcome at hospital discharge, 3 and 6 months 5. Health related quality of life at 3 and 6 months 6. Hospital length of stay 7. Intensive care length of stay	—

Measure

Time frame

1. Survived event (sustained ROSC, with spontaneous circulation until admission and transfer of care to medical staff at the receiving hospital) 2. Survival to hospital discharge (the point at which the patient is discharged from the hospital acute care unit regardless of neurological status, outcome or destination) 3, 6 and 12 months 3. Neurological outcome at hospital discharge, 3 and 6 months 5. Health related quality of life at 3 and 6 months 6. Hospital length of stay 7. Intensive care length of stay

—

Countries

United Kingdom

Outcome results

None listed